. 2021 Dec 29;5:100101. doi: 10.1016/j.rcsop.2021.100101

Table 4.

Drugs with positive results in COVID-19.

Drug	Recommended dosing regimen	Suitable at what stage	Randomized trial with positive outcome	Positive outcome	Potential risk	Evidence
Dexamethasone	Severe: 6 mg orally or IV infusion once daily for up to 10 days (or until hospital discharge if sooner) Critical: 20 mg IV once a day for 5 days, then 10 mg IV once a day for 5 days	Severe-to-critical	RECOVERY⁸	Mortality	Hyperglycaemia, delayed viral clearance	Effective
Dexamethasone		Severe-to-critical	CoDEX³²	Clinical recovery	Hyperglycaemia, delayed viral clearance	Effective
Ivermectin	0.4 mg/kg (maximum 24 mg) once daily for 4 days	Mild-to-severe	IRCT20200408046987N1¹⁵	Mortality	–	Inconclusive
Ivermectin	0.4 mg/kg (maximum 24 mg) once daily for 4 days	Mild-to-severe	NCT04668469 ¹⁶	Mortality	–	Inconclusive
Remdesivir	IV 200 mg loading dose on day 1, followed by a 100 mg maintenance dose administered daily on days 2 through 10 or until hospital discharge	Moderate-to-severe	ACTT-1¹⁸	Time to clinical recovery	AKI, transaminitis	Possibly effective
Remdesivir		Moderate-to-severe	ACTT-1¹⁸	Mortality	AKI, transaminitis	Possibly effective
Budesonide	DPI 800 μg twice daily for 14 days	Mild	PRINCIPLE¹¹	Time to clinical recovery	–	Possibly effective
Budesonide	DPI 800 μg twice daily for 14 days	Mild	STOIC¹²	Time to clinical recovery	–	Possibly effective
Methylprednisolone	IV 250 mg once daily 3 days	Severe	IRCT20200404046947N1³³	Mortality	Hyperglycaemia, delayed viral clearance	Possibly effective
Heparin	Enoxaparin: SC 1 mg/kg twice daily Unfractionated heparin: IV infusion to target for aPTT of 1.5 to 2.5 times the upper limit of normal	Mild-to-critical	ATTACC, ACTIV-4a, and REMAP-CAP multi-platform trials²⁶^,²⁷	Thromboembolic events	Beeding	Possibly effective